Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

Rafael Fonseca, S. A. Van Wier, W. J. Chng, R. Ketterling, Martha Lacy, Angela Dispenzieri, Peter Leif Bergsagel, S Vincent Rajkumar, P. R. Greipp, Mark R Litzow, T. Price-Troska, K. J. Henderson, G. J. Ahmann, Morie Gertz

Research output: Contribution to journalArticle

145 Citations (Scopus)

Abstract

A specific role for increased level of expression of CKS1B, as a consequence of chromosome 1q21 copy number gain, has been postulated as both pathogenic, as well as a powerful clinical prognostic factor in multiple myeloma (MM). The purpose of this study is to determine the clinical associations and prognostic impact of copy number gain at chromosome 1q21 (with a bacteria artificial chromosome clone containing CKS1B) and CKS1B gene level of expression in MM. We studied the chromosome region 1q21 for copy number change in a cohort of myeloma patients treated by high-dose therapy with stem-cell rescue (HDT) (n=159). A separate cohort of patients, treated by HDT was studied for CKS1B messenger RNA expression by gene expression profiling (n=67). 1q21 gain was then correlated with clinical parameters and survival. Gain of 1q21 copy number was detected in about a third of MM and was associated with more proliferative disease and poor-risk cytogenetic categories such as t(4;14), and chromosome 13 deletion. Both 1q21 gain and increase gene expression level were significantly associated with reduced survival. However, neither is an independent prognostic marker in MM on multivariate Cox proportional hazard analysis.

Original languageEnglish (US)
Pages (from-to)2034-2040
Number of pages7
JournalLeukemia
Volume20
Issue number11
DOIs
StatePublished - Nov 2006

Fingerprint

Multiple Myeloma
Fluorescence In Situ Hybridization
Chromosomes
Artificial Chromosomes
Gene Expression
Chromosomes, Human, Pair 13
Chromosome Deletion
Survival
Gene Expression Profiling
Cytogenetics
Stem Cells
Clone Cells
Bacteria
Messenger RNA
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. / Fonseca, Rafael; Van Wier, S. A.; Chng, W. J.; Ketterling, R.; Lacy, Martha; Dispenzieri, Angela; Bergsagel, Peter Leif; Rajkumar, S Vincent; Greipp, P. R.; Litzow, Mark R; Price-Troska, T.; Henderson, K. J.; Ahmann, G. J.; Gertz, Morie.

In: Leukemia, Vol. 20, No. 11, 11.2006, p. 2034-2040.

Research output: Contribution to journalArticle

@article{c035a2896bb64c93b84f2cab8ed95404,
title = "Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma",
abstract = "A specific role for increased level of expression of CKS1B, as a consequence of chromosome 1q21 copy number gain, has been postulated as both pathogenic, as well as a powerful clinical prognostic factor in multiple myeloma (MM). The purpose of this study is to determine the clinical associations and prognostic impact of copy number gain at chromosome 1q21 (with a bacteria artificial chromosome clone containing CKS1B) and CKS1B gene level of expression in MM. We studied the chromosome region 1q21 for copy number change in a cohort of myeloma patients treated by high-dose therapy with stem-cell rescue (HDT) (n=159). A separate cohort of patients, treated by HDT was studied for CKS1B messenger RNA expression by gene expression profiling (n=67). 1q21 gain was then correlated with clinical parameters and survival. Gain of 1q21 copy number was detected in about a third of MM and was associated with more proliferative disease and poor-risk cytogenetic categories such as t(4;14), and chromosome 13 deletion. Both 1q21 gain and increase gene expression level were significantly associated with reduced survival. However, neither is an independent prognostic marker in MM on multivariate Cox proportional hazard analysis.",
author = "Rafael Fonseca and {Van Wier}, {S. A.} and Chng, {W. J.} and R. Ketterling and Martha Lacy and Angela Dispenzieri and Bergsagel, {Peter Leif} and Rajkumar, {S Vincent} and Greipp, {P. R.} and Litzow, {Mark R} and T. Price-Troska and Henderson, {K. J.} and Ahmann, {G. J.} and Morie Gertz",
year = "2006",
month = "11",
doi = "10.1038/sj.leu.2404403",
language = "English (US)",
volume = "20",
pages = "2034--2040",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

AU - Fonseca, Rafael

AU - Van Wier, S. A.

AU - Chng, W. J.

AU - Ketterling, R.

AU - Lacy, Martha

AU - Dispenzieri, Angela

AU - Bergsagel, Peter Leif

AU - Rajkumar, S Vincent

AU - Greipp, P. R.

AU - Litzow, Mark R

AU - Price-Troska, T.

AU - Henderson, K. J.

AU - Ahmann, G. J.

AU - Gertz, Morie

PY - 2006/11

Y1 - 2006/11

N2 - A specific role for increased level of expression of CKS1B, as a consequence of chromosome 1q21 copy number gain, has been postulated as both pathogenic, as well as a powerful clinical prognostic factor in multiple myeloma (MM). The purpose of this study is to determine the clinical associations and prognostic impact of copy number gain at chromosome 1q21 (with a bacteria artificial chromosome clone containing CKS1B) and CKS1B gene level of expression in MM. We studied the chromosome region 1q21 for copy number change in a cohort of myeloma patients treated by high-dose therapy with stem-cell rescue (HDT) (n=159). A separate cohort of patients, treated by HDT was studied for CKS1B messenger RNA expression by gene expression profiling (n=67). 1q21 gain was then correlated with clinical parameters and survival. Gain of 1q21 copy number was detected in about a third of MM and was associated with more proliferative disease and poor-risk cytogenetic categories such as t(4;14), and chromosome 13 deletion. Both 1q21 gain and increase gene expression level were significantly associated with reduced survival. However, neither is an independent prognostic marker in MM on multivariate Cox proportional hazard analysis.

AB - A specific role for increased level of expression of CKS1B, as a consequence of chromosome 1q21 copy number gain, has been postulated as both pathogenic, as well as a powerful clinical prognostic factor in multiple myeloma (MM). The purpose of this study is to determine the clinical associations and prognostic impact of copy number gain at chromosome 1q21 (with a bacteria artificial chromosome clone containing CKS1B) and CKS1B gene level of expression in MM. We studied the chromosome region 1q21 for copy number change in a cohort of myeloma patients treated by high-dose therapy with stem-cell rescue (HDT) (n=159). A separate cohort of patients, treated by HDT was studied for CKS1B messenger RNA expression by gene expression profiling (n=67). 1q21 gain was then correlated with clinical parameters and survival. Gain of 1q21 copy number was detected in about a third of MM and was associated with more proliferative disease and poor-risk cytogenetic categories such as t(4;14), and chromosome 13 deletion. Both 1q21 gain and increase gene expression level were significantly associated with reduced survival. However, neither is an independent prognostic marker in MM on multivariate Cox proportional hazard analysis.

UR - http://www.scopus.com/inward/record.url?scp=33750327901&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750327901&partnerID=8YFLogxK

U2 - 10.1038/sj.leu.2404403

DO - 10.1038/sj.leu.2404403

M3 - Article

C2 - 17024118

AN - SCOPUS:33750327901

VL - 20

SP - 2034

EP - 2040

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 11

ER -